Diabetes Group Pushes Broader Use Of HbA1c Test For Disease Diagnosis
This article was originally published in The Gray Sheet
Executive Summary
The American Diabetes Association is seeking broader support from government agencies for use of the hemoglobin A1c (HbA1c) test as a screening and diagnostic tool for Type 2 diabetes
You may also be interested in...
New Products In Brief
Bausch & Lomb gets approval for first-of-a-kind intraocular lens. Roche HbA1c assay is first to be cleared to diagnose diabetes. More product launches and approvals from the past week.
FDA letter to HbA1c test makers
FDA is encouraging makers of hemoglobin A1c (HbA1c) assays to meet with the agency if they wish to pursue new diagnostic claims for their blood tests based on new data and updated guidance from the American Diabetes Association. ADA recently updated its recommendations for diabetes treatment standards to state that HbA1c test values of greater than or equal to 6.5% may be used to diagnose diabetes. However, no HbA1c test has yet been cleared by FDA with a diagnosis claim. The tests are cleared to monitor long-term glucose control in diabetes patients
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.